14-day Premium Trial Subscription Sign Up For FreeGet Free

$5.51 (-1.25%)

Volume: 833k

Closed: Jan 21, 2022

Hollow Logo Score: -1.259

Chimerix Stock Forecast

$5.51 (-1.25%)

Volume: 833k

Closed: Jan 21, 2022

Score Hollow Logo -1.259

Chimerix Company Profile

2505 Meridian Parkway

Durham NC 27713



Industry: Biotechnology

Sector: Healthcare



Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral antivirals in the areas of unmet medical needs in the United States. The company’s lead product candidate is brincidofovir (CMX001), a nucleotide analog, which is in Phase III clinical trials for the prevention of cytomegalovirus (CMV) in allogeneic hematopoietic cell transplant (HCT) recipients and in kidney transplant recipients, as well as to treat adenovirus infection in allogeneic HCT patients. It is also developing CMX157, a nucleotide analog that is in Phase II clinical stage for the treatment of HIV and hepatitis B virus infection. The company’s preclinical testing product comprises CMX669, a compound with in vitro activity for the treatment of BK virus and CMV. It has a license agreement with ContraVir Pharmaceuticals for the development and commercialization of brincidofovir and CMX157 for certain antiviral indications; and BARDA for the development of brincidofovir for the treatment of smallpox. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE